These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29572732)

  • 1. Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2018 Jun; 18(2):119-128. PubMed ID: 29572732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2017 Sep; 17(3):419-425. PubMed ID: 28744772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ
    Clin Drug Investig; 2015 Dec; 35(12):815-22. PubMed ID: 26507617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
    Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
    Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
    Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
    Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study.
    Cánovas-Martínez L; Carceller-Ruiz JJ; Díaz-Parada P; Illodo-Miramontes G; Freire-Vila E; De la Iglesia-López A; Iglesias BG; López-Ulloa B; Domínguez-Suárez E; Camba-Rodríguez A
    Clin Drug Investig; 2015 Mar; 35(3):169-77. PubMed ID: 25655006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen.
    Mercadante S; Prestia G; Casuccio A
    Curr Med Res Opin; 2013 Nov; 29(11):1527-32. PubMed ID: 23869428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
    Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
    Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
    Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.